CXCL17 and ICAM2 are associated with a potential anti-tumor immune response in early intraepithelial stages of human pancreatic carcinogenesis
View abstract on PubMed
Summary
This summary is machine-generated.Early pancreatic cancer immune surveillance involves CXCL17 and ICAM2, which promote anti-tumor immunity in precursor lesions. These molecules disappear as tumors progress to carcinoma, shifting the immune response towards tolerance.
Area Of Science
- Oncology
- Immunology
- Gastroenterology
Background
- Tumor progression involves dynamic changes in anti-tumor immunity, but the timing of immune evasion remains unclear.
- Intraductal papillary mucinous neoplasm (IPMN) represents an intraepithelial precursor to pancreatic cancer, progressing through adenoma to carcinoma stages.
- Understanding immune system interactions during pancreatic carcinogenesis is crucial for therapeutic development.
Purpose Of The Study
- To investigate the temporal changes in the human anti-tumor immune response during pancreatic tumor development.
- To identify molecular mechanisms underlying the transition from immune surveillance to immune tolerance in pancreatic carcinogenesis.
Main Methods
- Immunohistochemical analysis of tumor-infiltrating lymphocytes and dendritic cells in IPMN patient samples.
- Comparison of gene expression profiles across different stages of IPMN development (adenoma to carcinoma).
- Utilized syngeneic mouse models to analyze the biological functions of identified genes.
Main Results
- A shift from anti-tumor immune response to immune tolerance was observed between intraductal papillary mucinous adenoma (IPMA) and carcinoma (IPMC) stages.
- Chemokine (C-X-C motif) ligand 17 (CXCL17) and intercellular adhesion molecule 2 (ICAM2) expression was upregulated in IPMA but absent in IPMC.
- CXCL17 and ICAM2 induced immature myeloid dendritic cell infiltration and enhanced tumor cell susceptibility to cytotoxic T-cell-mediated lysis, contributing to anti-tumor immunity.
Conclusions
- Immune surveillance is active during the early intraepithelial stages of human pancreatic carcinogenesis.
- The expression of CXCL17 and ICAM2 plays a key role in mediating this early anti-tumor immune response.
- Loss of CXCL17 and ICAM2 expression correlates with the development of immune tolerance in advanced pancreatic neoplasia.